Pd-modified SnO 2 nanocrystals, with a Pd/Sn nominal atomic ratio of 0.025, were prepared by injecting SnO 2 sols and a Pd precursor solution into tetradecene and dodecylamine at 160 °C. Two different doping procedures were investigated: in co-injection, a Pd acetylacetonate solution in chloroform was mixed with the SnO 2 sol before the injection; in sequential injection, the Pd solution was injected separately after the SnO 2 sol. The obtained suspensions were heated at the resulting 80 °C temperature, then the product was collected by centrifugation and dried at 80 °C. When using co-injection, in the dried products PdO and Pd nanoparticles were observed by high-resolution transmission electron microscopy. Only SnO 2 nanocrystals were observed in dried products prepared by sequential injection. After heat-treatment at 500 °C, no Pd species were observed for both doping procedures. Moreover, X-ray photoelectron spectroscopy showed that, in both the doping procedures, after heat-treatment Pd is distributed only into the SnO 2 nanocrystal structure. This conclusion was reinforced by the measurement of the electrical properties of Pd-doped nanocrystals, showing a remarkable increase of the electrical resistance if compared with pure SnO 2 nanocrystals. This result was interpreted as Pd insertion as a dopant inside the cassiterite lattice of tin dioxide. The addition of Pd resulted in a remarkable improvement of the gas-sensing properties, allowing the detection of carbon monoxide concentrations below 50 ppm and of very low concentrations (below 25 ppm) of other reducing gases such as ethanol and acetone.
No takes yet. Share an insight, caveat, or question.
Epifani et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: